The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...

FDA is encouraging NDA holders for gels, patches, and injectables to discuss sNDAs for treating low libido in idiopathic hypogonadism, a group currently excluded from labeled indications. April 30, ...

Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US. The first US commercial surgical case using the Hugo robot-assisted ...

VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...

Break Wave lithotripsy device uses low-pressure ultrasound to fragment kidney stones non-invasively, requiring no anesthesia. The device offers a new treatment option for symptomatic and asymptomatic ...

The first-ever guideline on genitourinary syndrome of menopause (GSM) was released, providing evidence-based guidance for managing this condition in urologic care. The FDA removed the black box ...

Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...

Atezolizumab, guided by ctDNA, significantly improves DFS and OS in MIBC patients, as shown in the IMvigor011 trial. ctDNA can identify molecular residual disease, enabling targeted treatment and ...

Nivolumab significantly improves DFS, OS, and DSS in high-risk muscle-invasive urothelial carcinoma, especially in patients with PD-L1 expression ≥1%. The study's 5-year follow-up confirms nivolumab's ...

The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

The updated guideline emphasizes a patient-centered, risk-based approach, prioritizing symptom resolution and antimicrobial stewardship over microbial eradication. New recommendations include ...